

Funder	Project Title	Funding	Strategic Plan Objective	Institution
National Institutes of Health	1/5-The Autism Biomarkers Consortium for Clinical Trials	\$778,917	4.1	Duke University
National Institutes of Health	2/5-The Autism Biomarkers Consortium for Clinical Trials	\$876,168	4.1	Boston Children's Hospital
National Institutes of Health	3/5-The Autism Biomarkers Consortium for Clinical Trials	\$781,699	4.1	University of California, Los Angeles
National Institutes of Health	4/5-The Autism Biomarkers Consortium for Clinical Trials	\$734,661	4.1	University of Washington
National Institutes of Health	5/5-The Autism Biomarkers Consortium for Clinical Trials	\$820,733	4.1	Yale University
National Institutes of Health	Administrative Core	\$859,633	4.1	Yale University
National Institutes of Health	A Simultaneous PET/MR Study of Striatal Dopamine Binding in Autism	\$211,400	4.Core/Other	University of North Carolina at Chapel Hill
Brain & Behavior Research Foundation	Characterization of synaptic and neural circuitry dysfunction underlying ASD-like behaviors using a novel genetic mouse model	\$45,000	4.Core/Other	Duke University
National Institutes of Health	Data Acquisition and Analysis Core	\$1,447,019	4.1	Yale University
National Institutes of Health	Data Coordinating Core	\$764,690	4.1	Yale University
Simons Foundation	Detecting and Treating Social Impairments in a Monkey Model	\$272,775	4.1	Stanford University
Department of Defense - Army	Development of Novel Drugs Targeting Serotonin Receptors to Treat Motor, Social, Cognitive, and Sensory Domains of Autism Spectrum Disorder Using Mouse Models	\$318,322	4.1	Northeastern University
Department of Defense - Army	Development of Novel Drugs Targeting Serotonin Receptors to Treat Motor, Social, Cognitive, and Sensory Domains of Autism Spectrum Disorder Using Mouse Models	\$268,725	4.1	Mercer University
National Institutes of Health	Effects of Chronic Intranasal Oxytocin	\$1,038,234	4.1	University of California, Davis
Department of Defense - Army	Examination of the mGluR-mTOR pathway for the identification of potential therapeutic targets to treat fragile X	\$0	4.1	University of Pennsylvania
Simons Foundation	High-throughput drug discovery in zebrafish models of ASD risk genes	\$125,000	4.1	Yale University
Brain & Behavior Research Foundation	Investigations of a Proposed Molecular Feedback Loop in Cortical Neurons in Psychiatric Pathogenesis	\$25,000	4.1	University of California, San Francisco
National Institutes of Health	Longitudinal MRI Study of Brain Development in Fragile X	\$764,598	4.1	Stanford University
National Institutes of Health	Modeling The Serotonin Contribution to Autism Spectrum Disorders	\$224,237	4.1	Vanderbilt University
Brain & Behavior Research Foundation	Modulation of the Oxytocin System in a Mouse Model of Autism Spectrum Disorder (ASD)	\$32,158	4.1	University of the Basque Country

Funder	Project Title	Funding	Strategic Plan Objective	Institution
Simons Foundation	Neural circuitry linking oxytocin deficiency and social impairment in ASD	\$75,000	4.1	University of California, Los Angeles
National Institutes of Health	Novel Genetic Models of Autism	\$625,949	4.Core/Other	University of Texas Southwestern Medical Center
Department of Defense - Army	Novel therapeutic targets to treat social behavior deficits in autism and related disorders	\$0	4.1	University of Texas Health Science Center at San Antonio
National Institutes of Health	Oxytocin Receptors and Social Behavior	\$440,363	4.1	Emory University
Simons Foundation	Potassium channels as therapeutic targets in autism	\$0	4.1	Administrators of the Tulane Educational Fund
National Institutes of Health	Pre-clinical evaluation of oxytocin for ASD treatment discovery	\$196,165	4.1	University of California, Davis
National Institutes of Health	Prefrontal function in the Shank3-deficient rat: A first rat model for ASD	\$457,912	4.1	Icahn School of Medicine At Mount Sinai
National Institutes of Health	Regulation of 22q11 Genes in Embryonic and Adult Forebrain	\$445,484	4.1	George Washington University
Simons Foundation	Regulation of KCC2 as a target for treatment of Autism	\$0	4.1	University Laval
National Institutes of Health	Temporal Single Cell RNAseq to Identify Genes and Pathways Affected by 15q11.2 Duplication in Autism iPSC-Derived Differentiating Cortical Neurons	\$224,482	4.1	Juovbio Pharmaceuticals, Inc.
Brain & Behavior Research Foundation	Whole Brain Mapping of the Effects of Intranasal Oxytocin in CNTNAP2 KO Mouse Model of Autism	\$18,819	4.1	Cold Spring Harbor Laboratory

